Dr. Burtness on Immunotherapy Resistance in Head and Neck Cancer

Barbara Burtness, MD
Published: Wednesday, Jul 26, 2017



Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.

Immunotherapy is producing durable responses across malignancies, but there are still many patients who do not respond.

Burtness asks if the community has turned their back on targeted therapy too quickly. There may be promise in synthetic lethal approaches with targeted therapies, she adds.



Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.

Immunotherapy is producing durable responses across malignancies, but there are still many patients who do not respond.

Burtness asks if the community has turned their back on targeted therapy too quickly. There may be promise in synthetic lethal approaches with targeted therapies, she adds.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x